As always, take these notes with a grain of salt.  Sometimes I can't read my own handwriting.  I haven't gone to great lengths to format this post, but I'm sure you'd rather have my notes, than having them "pretty".

In any event, the AGM was, from my point of view, VERY positive!!  We are going to be a group of happy shareholders if everything plays out as hoped.

I'm not going to focus too much on the things that you can see/hear in the webcast, but I will focus on Q&A and later, side discussions with Don.  I'll post my notes for Zenith on the Zenith forum as soon as I can get to it.

Things got underway right at 1pm MDT.  Went through the normal election of directors, KPMG as auditors, compensation for staff and passed the special resolution for up to 1:5 share consolidation.  Probably around 100 people in attendance.  Many familiar faces.  End of formal part.

1:15 Management presentation - a lot of this you can probably hear on the webcast, but I'll repeat a few things here, just cause I feel really excited.

Talked about how RVX is finally being recognized for its leadership in this area of epigenetics.  Don feels we still have a 10 year lead on competitors.  We have a lot of world class researchers not only working for us, but also associated with us.

BETonMACE is fully enrolled; China was at end of June; others were end of Feb

1900 patients have been dosed.  There was a question in the Q&A about why not 3000+ but it is because 1/2 the folks in BETonMACE are on placebo.

Mentioned new timelines for things in the pipeline:

   CKD - Q1 2019

   Fabry - Q4 2018

   PAH - Q3 2019

   Vascular Dementia - Q2 2019

Apparently all patients interviewed want to stay on the treatment.  Some have been on close to 36 months.  That speaks volumes to me! 

14 countries already approved if phase 3 is OK.

Dosing likely to stop at 250-270 MACE events

SSRA not beneficial - no reason to do it.  We were fully enrolled in Feb 2018.  SSRA will result it a bit of a penalty anyways if done (1-2%).  I wasn't quite clear on why, but my assumption is that it would add to the timeline without significant advantage to doing it.

Approximately 200 events have been adjudicated with 10-15 /mo occuring (more in the winter than in the summer).

Full outcomes to be presented in 2019 at some major conferences, but top line results should be available in Q1, if things go as per plan.  This was a cautious prediction - could be sooner.

Slide 26 - talk on CKD.  Nephrologists are thrilled with new approaches to this disease.  Planning on launching kidney triaks in China - Hepalink to pay.  Don leaving tomorrow for further discussions.  (Hope this isn't like "Mexico will pay for the wall" - I don't think so)

20 more compounds in the pipeline, some BD2 selective.  Don was quite excited about how some of these might work and how they might be applied.

Work still onlgoing for US listing.  It sounds like it could happen, but at the right time.

Don't have any US pateitn in trial.  We already have enough of an ethnic mix to handle the diverse population in US.  Saves time and money to not have to conduct a trial there.  FDA will accept results from BETonMACE.

Really happy to have Rothschild as adviser.  More analyst coverage coming.

-------------------------------

Q&A

Question about lead drug and followon compounds.  20 in the works with very exciting properties.  BD2, autoimmune, etc.  Feels that there will be a lineup of potential partners once info comes out about BETonMACE.

Question about when top line data will be released.  Hard to estimate but should be early Q1.  

Will other indications (nephrology, etc) be revealed at that time?  Maybe, but would prefer to present data after analysis at major conferences instead, in front of 5-6K audiences.  Hope to be doing that by mid 2019.

Question about 1900 patients mentioned in slides.   Difference is that 1200 of current patients are on placebo.  So 1200

Are we fully financed to end of trial?  No, we always need money.  We are in good shape, but mostly we are intrigued by regional licensing.  Going well.

NASDAQ listing?  Just had a board meeting in morning on this topic.  Hired Rothschild to step us through this procedure.  Vote today allows us to take the reverse split if required.  If things go as expected, we are hoping we won''t have to.  May go into "quiet" time if this actually takes place.  By that, I imagine he means "blackout period" for insiders.

US Patients in trial?  Don't need them.  FDA agrees (see earlier comments).  Need to match ethnic makeup of US.  We've done that.  Big cost savings.  

Spinoffs for other compounds? Not yet - time will tell. 

Big Pharma discussions?  Will get additional data at time results are released.  We have preference for the ones that are able to deal with CV, Renal,  and Cognitive components.   Nobody will jump in before top line data released.  Keep pushing forward to finish line.

More analyst coverage to come in next year.  Very impressed with Rothschild plans for introducing Resverlogix to potential deep pockets.

------------------

That's it from my side, folks.  Hope you share my enthusiasm.  I honestly believe Don and the rest of the RVX folks have our best interests in mind.  The results will certainly prove it out one way or another in the near future.  Like many of you, I've been in this game for a long time and I believe we're in the home stretch.

I believe this drug can help many millions of folks who suffer from these diseases.  Have they found something that is truly a game-changer?  I think so.  Let's hope the rest of the world agrees with us.

GLTA, DYODD

masila

PS I may not get to the Zenith notes until tomorrow, but things are REALLY moving there.  Stay tuned.